Cantor Fitzgerald Brokers Reduce Earnings Estimates for REGN

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Equities research analysts at Cantor Fitzgerald decreased their FY2024 earnings estimates for Regeneron Pharmaceuticals in a research report issued on Tuesday, October 29th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaceutical company will post earnings of $37.43 per share for the year, down from their prior forecast of $38.67. Cantor Fitzgerald currently has a “Neutral” rating and a $1,015.00 target price on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $37.60 per share.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company’s revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the business earned $8.79 EPS.

A number of other equities research analysts have also commented on REGN. TD Cowen raised their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Piper Sandler lifted their target price on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. Finally, Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,101.00.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $922.79 on Thursday. Regeneron Pharmaceuticals has a 12 month low of $772.84 and a 12 month high of $1,211.20. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The stock has a market cap of $101.73 billion, a PE ratio of 24.44, a price-to-earnings-growth ratio of 3.20 and a beta of 0.12. The business has a fifty day simple moving average of $1,072.53 and a 200-day simple moving average of $1,040.65.

Insider Transactions at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 487 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds have recently modified their holdings of REGN. Brown Lisle Cummings Inc. lifted its position in Regeneron Pharmaceuticals by 18.2% in the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 10 shares during the period. Sachetta LLC raised its stake in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares in the last quarter. Adirondack Trust Co. lifted its holdings in shares of Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after acquiring an additional 10 shares during the period. UMB Bank n.a. boosted its position in shares of Regeneron Pharmaceuticals by 1.1% during the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after acquiring an additional 10 shares in the last quarter. Finally, Team Hewins LLC increased its stake in Regeneron Pharmaceuticals by 2.5% in the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $434,000 after acquiring an additional 11 shares during the period. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.